Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,252.80
(
-1.87%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,996.04
(
-0.08%
)
News Focus
News Focus
Post# of 257578
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: drbio45 post# 75096

Friday, 03/27/2009 9:20:08 AM

Friday, March 27, 2009 9:20:08 AM

Post# of 257578
MNTA – Thanks, drbio, for the Leerink Swann report.

Joseph Schwartz (analyst): Teva likely submitted the CP seeking to stall M-356 [generic Copaxone] in its regulatory pathway…

“Likely” strikes me as unduly timid on the analyst’s part; is there another reason why Teva would have submitted the Copaxone CP? (Rhetorical question—no need to reply.)


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today